Explore All 401 Growth Capital Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | January 5, 2021 |
| Target | Seran |
| Sector | Life Science |
| Investor(s) | Vivo Capital |
| Deal Type | Growth Capital |
FILTER BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 5.3B USD |
| Size | Mega |
| Type | Sector Focused |
Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1996 and is headquartered in Palo Alto, California.
| Deal Context for Investor | # |
|---|---|
| Overall | 21 of 29 |
| Sector: Life Science | 13 of 18 |
| Type: Growth Capital | 3 of 5 |
| State: Oregon | 1 of 1 |
| Country: United States | 15 of 19 |
| Year: 2021 | 2 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-01 |
Evaheart
Shanghai, China Evaheart is a high-tech enterprise focusing on the research and development and production of innovative medical devices in the field of heart failure and panvascular diseases. Evaheart was founded in 2014 and is based in Shanghai, China. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-13 |
IO Biotech
Copenhagen, Denmark IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech's pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2014 and is based in Copenhagen, Denmark. |
Buy | - |
